Siren, L.L.C. Vaxcyte, Inc. Transaction History
Siren, L.L.C.
- $2 Trillion
- Q3 2024
A detailed history of Siren, L.L.C. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 299,991 shares of PCVX stock, worth $27.8 Million. This represents 1.71% of its overall portfolio holdings.
Number of Shares
299,991Holding current value
$27.8 Million% of portfolio
1.71%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
325Shares Held
116MCall Options Held
315KPut Options Held
207K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.06 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$1.01 Billion0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$921 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$805 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$454 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.5B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...